BPC 157 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
==== Biomarkers of exposure ==== Several tests can determine exposure to benzene. Benzene itself can be measured in breath, blood, or urine, however such testing is usually limited to the first 24 hours post-exposure due to the relatively rapid removal of the chemical by exhalation or biotransformation. The majority of people in developed countries have measureable baseline levels of benzene and other aromatic petroleum hydrocarbons in their blood. In the body, benzene is enzymatically converted to a series of oxidation products including muconic acid, phenylmercapturic acid, phenol, catechol, hydroquinone and 1,2,4-trihydroxybenzene. Most of these metabolites have some value as biomarkers of human exposure, since they accumulate in the urine in proportion to the extent and duration of exposure, and they may still be present for some days after exposure has ceased. The current ACGIH biological exposure limits for occupational exposure are 500 μg/g creatinine for muconic acid and 25 μg/g creatinine for phenylmercapturic acid in an end-of-shift urine specimen.
== DNA == DNA quaternary structure is used to refer to the binding of DNA to histones to form nucleosomes, and then their organisation into higher-order chromatin fibres. The quaternary structure of DNA strongly affects how accessible the DNA sequence is to the transcription machinery for expression of genes. DNA quaternary structure varies over time, as regions of DNA are condensed or exposed for transcription. The term has also been used to describe the hierarchical assembly of artificial nucleic acid building blocks used in DNA nanotechnology. The quaternary structure of DNA refers to the formation of chromatin. Because the human genome is so large, DNA must be condensed into chromatin, which consists of repeating units known as nucleosomes. Nucleosomes contain DNA and proteins called histones. The nucleosome core usually contains around 146 DNA base pairs wrapped around a histone octamer. The histone octamer is made of eight total histone proteins, two of each of the following proteins: H2A, H2B, H3, and H4. Histones are primarily responsible for shaping the nucleosomes, therefore drastically contributing to chromatin structure. Histone proteins are positively-charged and therefore can interact with the negatively-charged phosphate backbone of DNA. One portion of core histone proteins, known as histone tail domains, are extremely important for keeping the nucleosome tightly wrapped and giving the nucleosome secondary and tertiary structure. This is because the histone tail domains are involved in interactions between nucleosomes.
=== Pharmacodynamics === Nor-LSD showed 5- to 29-fold lower affinity for the serotonin 5-HT2 receptor compared to LSD (Ki = 30–158 nM vs. 5.4 nM, respectively). It also showed affinity for the serotonin 5-HT1 receptor. In another more recent study however, nor-LSD showed similar or even higher affinities, activational potencies, and/or efficacies at the serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors as LSD, whereas it showed 36-fold lower affinity for the serotonin 5-HT2C receptor compared to LSD. Nor-LSD failed to completely substitute for LSD in rodent drug discrimination tests even at very high doses. The greatest degree of substitution with nor-LSD was 75% at a dose of 7,420 nM/kg, whereas 100% substitution occurred with LSD at a dose of 186 nM/kg (a 40-fold lower dose). The ED50Tooltip median effective dose was 2,594 nM/kg for nor-LSD and 46 nM/kg for LSD. Hence, nor-LSD was approximately 56-fold less potent than LSD in terms of producing LSD-like effects in rodents and failed to produce full LSD-like effects even at the highest assessed dose. In another study, nor-LSD failed to produce LSD-like electroencephalogram (EEG) changes in rabbits.
== Kosmotropes and chaotropes == Highly charged ions interact strongly with water, breaking hydrogen bonds and inducing electrostatic structuring of nearby water, and are thus called "structure-makers" or "kosmotropes". Conversely, weak ions can disrupt the structure of water, and are thus called "structure-breakers" or "chaotropes". The order of the tendency of ions to make or break water structure is the basis of the Hofmeister series. Hofmeister discovered a series of salts that have consistent effects on the solubility of proteins and, as it was discovered later, on the stability of their secondary and tertiary structures. Anions appear to have a larger effect than cations, and are usually ordered as follows:
Sources: en.wikipedia.org
== Thermodynamics == The thermodynamics of metal ion complex formation provides much significant information. In particular it is useful in distinguishing between enthalpic and entropic effects. Enthalpic effects depend on bond strengths and entropic effects have to do with changes in the order/disorder of the solution as a whole. The chelate effect, below, is best explained in terms of thermodynamics. An equilibrium constant is related to the standard Gibbs free energy change for the reaction
===== Intersectional genomics ===== Nutritional genomics: A science studying the relationship between human genome, nutrition and health. Nutrigenetics studies the effect of genetic variations on the interaction between diet and health with implications to susceptible subgroups Nutrigenomics: Study of the effects of foods and food constituents on gene expression. Studies the effect of nutrients on the genome, proteome, and metabolome Pharmacogenomics investigates the effect of the sum of variations within the human genome on drugs; Pharmacomicrobiomics investigates the effect of variations within the human microbiome on drugs and vice versa. Toxicogenomics: a field of science that deals with the collection, interpretation, and storage of information about gene and protein activity within particular cell or tissue of an organism in response to toxic substances. Psychogenomics: Process of applying the powerful tools of genomics and proteomics to achieve a better understanding of the biological substrates of normal behavior and of diseases of the brain that manifest themselves as behavioral abnormalities. Applying psychogenomics to the study of drug addiction, the ultimate goal is to develop more effective treatments for these disorders as well as objective diagnostic tools, preventive measures, and eventually cures. Stem cell genomics: Helps in stem cell biology. Aim is to establish stem cells as a leading model system for understanding human biology and disease states and ultimately to accelerate progress toward clinical translation.
=== Adverse effects === DNP has a low therapeutic index, meaning that the dosage at which toxicity occurs is not much larger than that required to produce a desired effect. Individual tolerance to DNP's harmful short- and long-term effects varies greatly. The most common adverse effect reported is a rash, which could be maculopapular, urticarial, angioedema, or an exfoliative dermatitis. Cataracts can form, causing a permanent loss of vision in days to months of usage, and permanent deafness has also been reported. Other adverse effects reported include peripheral neuritis, agranulocytosis, and neutropaenia. Negative effects on the central nervous system, cardiovascular system, and bone marrow can occur. In animal studies, DNP acted as a teratogen, mutagen, and carcinogen and caused developmental and reproductive harm. An unusually yellow coloring of the skin, mucous membranes, sclera, urine, stomach contents, and internal organs is an indication of DNP exposure, but does not occur in every case. Contact with skin or inhalation can cause DNP poisoning. Symptoms are typically mild with dermal exposure, but inhalation can lead to systemic effects, the same way as oral exposure.
=== May === 1 May – Bob Brockie, biologist, cartoonist (National Business Review) and columnist (Dominion Post) (born 1932). 2 May – Sir Bob Jones, property magnate, writer, and politician, founder of the New Zealand Party (1983) (born 1939). 5 May Shane Richardson, motorcycle racer (born c. 1996). Shane Solomon, lawyer and Māori leader (Waikato Tainui) (born 1963). 6 May – Bill McCaw, rugby union player (Southland, national team), oldest living All Black (since 2023) (born 1927). 9 May – Fred Graham, rugby union player (New Zealand Māori), educator and sculptor, Te Tohu mō Te Arikinui Dame Te Atairangikaahu (2017), Arts Foundation of New Zealand Icon (since 2018) (born 1928). 13 May – Danny Lendich, businessman and midget car racing team owner, introduced Wendy's to New Zealand (1988) (born 1944). 14 May – Lionel Hill-Smith, Empire Games hurdler (1950) (born 1929). 15 May – Durham Havill, local politician and businessman, Mayor of Westland (1989–1998) (born 1944). 16 May – Tuppy Diack, rugby union player (Otago, Southland, national team) and administrator, president of the Otago Rugby Football Union (2005) (born 1930). 17 May – Clive Rennie, educator, principal of Rangitikei College (1986–1991), Mountainview High School (1997–2000) and Otago Boys' High School (2000–2014) (born 1944). 18 May – John Simpson, silversmith and fine arts academic (University of Canterbury) (born 1925). 21 May – Frank Gibson Jr., jazz drummer and drum tutor (born 1946). 23 May – Roger Bridge, businessman and political party official (National) (born 1958).
1930: Mexican civil engineer Concepción Mendizábal Mendoza became the first woman in Mexico to earn a civil engineering degree. 1930: Russian botanist and geneticist Elena Barulina published the first map of the international distribution of lentils and their wild relatives, a work that became the standard reference for researchers. 1932: Michiyo Tsujimura became the first Japanese woman to earn a doctorate in agriculture. She studied at the Tokyo Imperial University, and her doctoral thesis was entitled "On the Chemical Components of Green Tea". 1933: Hungarian scientist Elizabeth Rona received the Haitinger Prize from the Austrian Academy of Sciences for her method of extracting polonium. 1933: American bacteriologist Ruth Ella Moore became the first African-American woman to receive a PhD in the natural sciences, completing her doctorate in bacteriology at Ohio State University. 1933: Egyptian medical doctor Tawhida Abdel-Rahman became the first female doctor employed by the Egyptian Government Health Ministry. 1935: French chemist Irène Joliot-Curie received the Nobel Prize in Chemistry along with Frédéric Joliot-Curie "for their synthesis of new radioactive elements". 1935: American plant hybridist Grace Sturtevant, the "First Lady of Iris", received the American Iris Society's gold medal for her lifetime's work. 1936: American entomologist Edith Patch became the first female president of the Entomological Society of America. 1936: New Zealand mycologist Kathleen Maisey Curtis was elected the first female Fellow at the Royal Society of New Zealand.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.